It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

Women hugging

KISQALI® is used to treat adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer. This means the cancer is localized to the breast or could have spread to the lymph nodes in the region of the breast, with no detectable spread to other parts of the body, has been surgically removed, and has certain characteristics that increase the risk of the cancer returning. 

KISQALI® is used in combination with an aromatase inhibitor, which is used as hormonal anticancer therapy to prevent the cancer from coming back after surgery.

Here's where you can explore helpful tools and resources to support you on your KISQALI® treatment journey

Illustrative image of KISQALI® patient information brochure

Information brochure

A comprehensive brochure that can help you understand your breast cancer diagnosis. Inside, you'll find important information about your treatment with KISQALI®.

Download
Illustrative image of KISQALI® wallet card

Wallet card

This wallet-sized card may help your healthcare team have a better understanding of any potential symptoms you may be experiencing.
You can show it whenever you visit a hospital/pharmacy or clinic.

Download

If you prefer to have a physical copy of any of these resources, you can print the digital PDFs.

Printer icon

Here are some sources of information that you might find helpful: 

National: 

Canadian Cancer Society
Canadian Breast Cancer Network
rethink Breast Cancer

Provincial: 

BC Cancer
Cancer Care Ontario
Quebec Breast Cancer Foundation